Citigroup Begins Coverage on Structure Therapeutics (NASDAQ:GPCR)

Citigroup began coverage on shares of Structure Therapeutics (NASDAQ:GPCR - Free Report) in a report published on Friday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $60.00 price target on the stock.

GPCR has been the subject of several other research reports. William Blair started coverage on Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating on the stock. Stifel Nicolaus began coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a "buy" rating and a $50.00 price objective for the company. Finally, HC Wainwright restated a "buy" rating and set a $80.00 target price on shares of Structure Therapeutics in a report on Tuesday, April 22nd. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics presently has a consensus rating of "Buy" and an average target price of $78.63.

Structure Therapeutics Stock Performance

Structure Therapeutics stock traded up $0.46 during trading on Friday, reaching $27.55. 692,154 shares of the company's stock were exchanged, compared to its average volume of 922,021. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of -37.23 and a beta of -1.35. Structure Therapeutics has a 52-week low of $13.22 and a 52-week high of $62.74. The company's 50-day moving average is $20.52 and its two-hundred day moving average is $27.30.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. Analysts anticipate that Structure Therapeutics will post -0.82 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of GPCR. ANTIPODES PARTNERS Ltd raised its position in Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after purchasing an additional 553 shares during the last quarter. GAMMA Investing LLC lifted its position in Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after acquiring an additional 1,122 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Structure Therapeutics during the 4th quarter valued at $34,000. FNY Investment Advisers LLC bought a new stake in Structure Therapeutics in the 4th quarter worth about $40,000. Finally, Virtus ETF Advisers LLC lifted its holdings in Structure Therapeutics by 25.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after acquiring an additional 455 shares during the period. Institutional investors own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.